Prevalence of protease and reverse transcriptase drug resistance mutations over time in drug-naïve human immunodeficiency virus type 1-positive individuals in Rio de Janeiro, Brazil.
about
In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIVHIV-1 diversity and drug resistance mutations among people seeking HIV diagnosis in voluntary counseling and testing sites in Rio de Janeiro, BrazilSurveillance of HIV Transmitted Drug Resistance in Latin America and the Caribbean: A Systematic Review and Meta-AnalysisFrequency of human immunodeficiency virus type-2 in hiv infected patients in Maputo City, MozambiqueCo-infection by human immunodeficiency virus type 1 (HIV-1) and human T cell leukemia virus type 1 (HTLV-1): does immune activation lead to a faster progression to AIDS?Prevalence of human immunodeficiency virus drug resistance mutations and subtypes in drug-naive, infected individuals in the army health service of Rio de Janeiro, Brazil.Effect of natural polymorphisms in the HIV-1 CRF02_AG protease on protease inhibitor hypersusceptibilityA genotyping study of human immunodeficiency virus type-1 drug resistance in a small Brazilian municipality.Primary resistance of human immunodeficiency virus type 1 in a reference center in Recife, Pernambuco, Brazil.Human immunodeficiency virus-1 subtypes and antiretroviral drug resistance profiles among drug-naïve Brazilian blood donors.Overview of genotypic and clinical profiles of human immunodeficiency virus type 1-infected children in Rio de Janeiro, Brazil.Monitoring HIV drug resistance in treatment-naive individuals: molecular indicators, epidemiology and clinical implicationsTransmitted Resistance: An Overview and Its Potential Relevance to the Management of HIV-Infected Persons in Resource-Limited Settings
P2860
Q24672993-7F0AF6F8-8F79-4B0D-8570-E866E45179D7Q28539348-2CFF8E93-732B-4F18-A739-8134B4719936Q28552242-97BEAA0A-B056-420F-8D70-18AE70617FD2Q30406079-9A52090F-1FAD-4A02-8EC8-02370FFB87A0Q33520335-42948646-C74B-4154-9A2B-3FEA35B16617Q35551677-47D64F69-74CF-46D1-A0C4-BB921F271E07Q35941273-EB93F998-58FD-4141-A671-BF85AD9D869AQ39743833-7D7BB8A1-A854-432C-8914-57FB661A2965Q45407361-8575B0F4-55EC-4608-BFF7-D7637FDDC72EQ45408530-DBC6AD4C-71FD-44FB-9331-0904B30E192EQ45548241-3363CCF7-A203-481F-9EFA-7BB825608ECBQ57708766-F04CFCFE-DBC4-406D-A916-F5BE444935ADQ57880269-5EE11353-5DD4-4155-B0F6-D0FC145C4761
P2860
Prevalence of protease and reverse transcriptase drug resistance mutations over time in drug-naïve human immunodeficiency virus type 1-positive individuals in Rio de Janeiro, Brazil.
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Prevalence of protease and rev ...... als in Rio de Janeiro, Brazil.
@ast
Prevalence of protease and rev ...... als in Rio de Janeiro, Brazil.
@en
Prevalence of protease and rev ...... als in Rio de Janeiro, Brazil.
@nl
type
label
Prevalence of protease and rev ...... als in Rio de Janeiro, Brazil.
@ast
Prevalence of protease and rev ...... als in Rio de Janeiro, Brazil.
@en
Prevalence of protease and rev ...... als in Rio de Janeiro, Brazil.
@nl
prefLabel
Prevalence of protease and rev ...... als in Rio de Janeiro, Brazil.
@ast
Prevalence of protease and rev ...... als in Rio de Janeiro, Brazil.
@en
Prevalence of protease and rev ...... als in Rio de Janeiro, Brazil.
@nl
P2093
P2860
P1476
Prevalence of protease and rev ...... als in Rio de Janeiro, Brazil.
@en
P2093
Ana T Dumans
Danuta Pieniazek
Kurt Hertogs
Marcelo A Soares
Marcia L Kalish
Veronique De Vroey
P2860
P304
P356
10.1128/AAC.46.9.3075-3079.2002
P407
P577
2002-09-01T00:00:00Z